Khaldoon Alaswad, MD
Interventional Cardiology · Detroit, MINPI 1093762205
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $189,393 of the $276,180 with a category attached, or 68.6%. 31 manufacturers reported payments, led by Boston Scientific at 57.7% of the total. Reporting peaked in 2019 at $119,188 and has fallen 91.1% since, to $10,637 in 2025. Among interventional cardiology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $746.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$159K
- Cardiovascular Systems Inc.$38K
- Abbott$25K
- Teleflex LLC$13K
- Asahi Intecc USA, Inc.$12K
- Abiomed$8K
- plus $20K from 25 others
Across 172 payments — averaging $4981.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$273K
- Livanova USA, Inc.$259K
- Cardiovascular Systems Inc.$181K
- Arrow International, Inc.$66K
- Biotronik Inc.$36K
- Abbott$29K
- plus $13K from 1 others
What the payments were for
- Consulting fees$52,21819%
- Speaking & faculty fees$189,39369%
- Travel & lodging$23,7379%
- Food & beverage$10,8324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 176 | $159,372 |
| Cardiovascular Systems Inc. | 27 | $37,870 |
| Abbott | 38 | $25,143 |
| Teleflex LLC | 18 | $13,371 |
| Asahi Intecc USA, Inc. | 9 | $12,467 |
| Abiomed | 13 | $7,880 |
| Livanova USA, Inc. | 12 | $7,085 |
| Arrow International, Inc. | 3 | $6,235 |
| Bard Peripheral Vascular, Inc. | 8 | $2,378 |
| Shockwave Medical, Inc | 9 | $1,082 |
| Inari Medical, Inc. | 10 | $824 |
| Vascular Solutions, Inc. | 1 | $500 |
| Edwards Lifesciences | 4 | $342 |
| Penumbra, Inc. | 2 | $300 |
| Philips North America LLC | 3 | $252 |
| Getinge USA Sales, LLC | 4 | $141 |
| Stryker | 2 | $132 |
| Biotronik Inc. | 1 | $118 |
| Medtronic(2 entities) | 4 | $112 |
| Cardiva Medical, Inc. | 3 | $87 |
| Reflow Medical Inc | 2 | $73 |
| Amgen | 5 | $72 |
| Kestra Medical Technology Services, Inc. | 1 | $54 |
| Chiesi USA, Inc. | 3 | $51 |
| Cardinal Health 200 LLC | 2 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $41 |
| Siemens Medical Solutions USA, Inc. | 2 | $35 |
| Recor Medical Inc | 1 | $31 |
| Verge Medical, Inc. | 1 | $31 |
| Cordis US CORP. | 2 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$66,843
- CROSSBOSS$60,244
- Xience V coronary stent system$24,453
- Diamondback Coronary$20,038
- Coronary Orbital Atherectomy System$17,648
- ASAHI PTCA Guide Wire$12,281
- GENERAL - THERAPIES$12,180
- TURNPIKE$12,135
- Impella$7,729
- GUIDELINER$4,744
- LifeSPARC$3,750
- Vitalyst$3,720
- TandemLife$3,135
- SYNERGY$2,625
- Diamondback Peripheral$2,430
- Watchman$1,629
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$858
- FLOWTRIEVER CATHETER, S$645
- CT THROMBECTOMY SYSTEM KIT$645
- Catheter - Specialty Access$500
How this compares
$276,180 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ezetimibe | 15 | $833 |
| Metoprolol Succinate | 21 | $494 |
| ClopidogrelClopidogrel Bisulfate | 24 | $397 |
| Cilostazol | 14 | $264 |
| Rosuvastatin Calcium | 12 | $172 |
| Atorvastatin Calcium | 14 | $144 |
| Lisinopril | 16 | $103 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Detroit
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Mir BasirDetroit$442K
- M Chadi AlraiesDetroit$216K
- Zaher HakimDetroit$92K
- Delair GardiDetroit$63K
- Brittany FullerDetroit$61K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.